Can beta-lactams be re-engineered to beat MRSA?

  title={Can beta-lactams be re-engineered to beat MRSA?},
  author={David Martin Livermore},
  journal={Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
  volume={12 Suppl 2},
Methicillin-resistant Staphylococcus aureus (MRSA) strains are important nosocomial pathogens worldwide and now are also of growing importance in community-acquired infection. Their resistance depends upon a supplementary peptidoglycan transpeptidase, PBP2' (PBP-2a), which continues to function when normal PBPs have been inactivated by beta-lactams. PBP2' is encoded by the mecA gene, which is carried by the staphylococcal cassette chromosome, a large and somewhat variable DNA insert of… CONTINUE READING
Highly Cited
This paper has 32 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 17 extracted citations

Optimizing therapy for MRSA pneumonia.

Seminars in respiratory and critical care medicine • 2007
View 7 Excerpts
Highly Influenced

Appropriate Targets for Antibacterial Drugs.

Cold Spring Harbor perspectives in medicine • 2016
View 2 Excerpts

A new antibiotic: lessons and perspectives.

International journal of clinical practice • 2008